NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01. Other Events.
issued a press release titled “Interim Phase 2 Data Demonstrate
Robust Response Rate with Indoximod in Combination with Keytruda
(pembrolizumab) for Patients with Advanced Melanoma at AACR
Plenary”
incorporated herein by reference.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated April 4, 2017, entitled Interim
Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary |
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer. NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information
NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session 00.00 at 23.09 with 666,762 shares trading hands.
